COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,386 Articles (22,816 medRxiv, 8,570 bioRxiv)

Most recent first Previous |  Page 874: Articles 8731-8740  | Next

Topologically engineered antibodies and Fc-fusion proteins: a new class of multifunctional therapeutic candidates for SARS-CoV-2, cancer, and other disease
Capon, D. J., Troitskaya, L., Chan, N. L. S., Fomin, M., Edman, U., Frank, B., Jin, J., Martinelli, R., Capon, B. Z., Ferguson, G. A., Gefter, M. L., Simmons, G.
10.1101/2022.03.23.485397 — Posted: 2022-03-23
Cellulosic copper nanoparticles and a hydrogen peroxide-based disinfectant protect Vero E6 cells against infection by viral pseudotyped particles expressing SARS-CoV-2, SARS-CoV or MERS-CoV Spike protein.
Brault, A., Nere, R., Prados, J., Boudreault, S., Bisaillon, M., Marchand, P., Couture, P., Labbe, S.
10.1101/2022.03.22.485373 — Posted: 2022-03-23
A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability
Voigt, E. A., Gerhardt, A., Hanson, D., Battisti, P., Reed, S., Singh, J., Mohamath, R., Jennewein, M. F., Bakken, J., Beaver, S., Press, C., Soon-Shiong, P., Paddon, C. J., Fox, C. B., Casper, C.
10.1101/2022.03.22.485230 — Posted: 2022-03-23
Intranasal Nanoemulsion Adjuvanted S-2P Vaccine Demonstrates Protection in Hamsters and Induces Systemic, Cell-Mediated and Mucosal Immunity in Mice
Ganesan, S., Acosta, H., Brigolin, C., Orange, K., Trabbic, K., Chen, C., Lien, C.-E., Lin, Y.-J., Lin, M.-Y., Chuang, Y.-S., Fattom, A., Bitko, V.
10.1101/2022.03.22.485323 — Posted: 2022-03-23
In silico analysis predicts a limited impact of SARS-CoV-2 variants on CD8 T cell recognition
Isaeva, O. I., Ketelaars, S. L. C., Kvistborg, P.
10.1101/2022.03.23.485487 — Posted: 2022-03-23
Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
Fang, Z., Peng, L., Lin, Q., Zhou, L., Yang, L., Feng, Y., Ren, P., Renauer, P. A., Park, J. J., Zhou, X., Wilen, C. B., Chen, S.
10.1101/2022.03.22.485418 — Posted: 2022-03-23
Jupytope: Computational extraction of structural properties of viral epitopes
Rashid, S., Ng, T. A., Kwoh, C. K.
10.1101/2022.03.22.484725 — Posted: 2022-03-23
Sequential appearance and isolation of a SARS-CoV-2 recombinant between two major SARS-CoV-2 variants in a chronically infected immunocompromised patient
Burel, E., Colson, P., Lagier, J.-C., LEVASSEUR, A., Bedotto, M., Lavrard, P., Fournier, P.-E., LA SCOLA, B., Raoult, D.
10.1101/2022.03.21.22272673 — Posted: 2022-03-23
Altered microRNA expression in severe COVID-19: potential prognostic and pathophysiological role
Garnier, N., Pollet, K., Fourcot, M., Caplan, M., Marot, G., Goutay, J., Labreuche, J., Soncin, F., Boukherroub, R., Hober, D., Lille COVID Research Network (LICORNE), , Szunerits, S., Poissy, J., Engelmann, I.
10.1101/2022.03.21.22272480 — Posted: 2022-03-23
Dynamics of anti-SARS-CoV-2 seroconversion in individual patients and at the population level
Szewczyk-Dabrowska, A., Budziar, W., Baniecki, K., Pikies, A., Harhala, M., Jedruchniewicz, N., Kazmierczak, Z., Gembara, K., Klimek, T., Witkiewicz, W., Nahorecki, A., Barczyk, K., Grata-Borkowska, U., Dabrowska, K.
10.1101/2022.03.20.22272651 — Posted: 2022-03-23

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).